ADRB2-Targeting Therapies for Prostate Cancer
نویسندگان
چکیده
منابع مشابه
Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor
Background: Recently, modification of T cells with chimeric antigen receptor (CAR) has been an attractive approach for adoptive immunotherapy of cancers. Typically, CARs contain a single-chain variable domain fragment (scFv). Most often, scfvs are derived from a monoclonal antibody of murine origin and may be a trigger for host immune system that leads to the T-cell clearance. Nanobody is a spe...
متن کاملTargeting in Cancer Therapies
Drug developers recruit and combine principles, procedures and strategies from chemistry, pharmacology, nanotechnology and biotechnology, focusing on the generation of functional vehicles as nano-carriers of drugs for improved stability and enhanced intracellular delivery.[...].
متن کاملNew therapies for castration-resistant prostate cancer.
Historical Progress in the Treatment of Metastatic Prostate Cancer The treatment of metastatic castration-resistant prostate cancer (mCRPC) has been substantially transformed over the past 2 decades. From traditional palliative treatments aimed at reducing cancer-related symptoms, significant progress has been made with United States Food and Drug Administration (FDA) approval of drugs targetin...
متن کاملKLK-targeted therapies for prostate cancer
Address correspondence to: Dr Hannu Koistinen Department of Clinical Chemistry, Biomedicum Helsinki, P.O. Box 63, FIN-00014 University of Helsinki, Finland Tel: +358 9 471 71734 e-mail: [email protected] E-mails: [email protected] (HK) [email protected] (JM) [email protected] (UHS)
متن کاملKLK-targeted Therapies for Prostate Cancer
Alternative treatments are urgently needed for prostate cancer, especially to address the aggressive metastatic castration-resistant disease. Proteolytic enzymes are involved in cancer growth and progression. The prostate produces several proteases, the most abundant ones being two members of the kallikrein-related peptidase (KLK) family, prostate-specific antigen (PSA) and KLK2. Despite the wi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancers
سال: 2019
ISSN: 2072-6694
DOI: 10.3390/cancers11030358